Novel Compounds for the Treatment of Obesity and reducing Glucose Levels

Berry Elliot, HUJI, School of Medicine - IMRIC, School of Public Health
Katzhendler Z"L Jehoshua, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research
Avraham Yosefa, HUJI, School of Medicine - IMRIC, School of Public Health

Yousef Najajreh, Al Quds University



  • A growing number of peoples worldwide are suffering from the health consequences of obesity.
  • As for today, Only one drug is currently approved for long-treatment of obesity-the lipase inhibitor Xenical. Use of this product has been limited by side effects.

 Our Innovation

  • The patent is covering Novel Active Compounds –derivatives of fatty acids and amino acids which may regulate feeding and body weight.
  • Compound X (the leading compound) and its derivatives represent novel compounds for the treatment of obesity which do not act on either CB1, TRPV1 or PPAR-α receptors (tested by MSD for receptor binding activity).
  • The compounds present new mechanisms of action (via POMC, NPY or FAAH (Fatty Acid Amide Hydrolase) inhibition in relation to known compounds on the market: Xenical (Lipase inhibition), Reductil (NE-5HT re-uptake inhibitor) and Rimonobant (CB1 receptor antagonist) (removed recently from the market).


  • Patent on new compounds which are small natural, organic molecules.
  • The Compounds are made of natural products which may be given orally and act in a dose-dependent manner.
  • Three (3)  compounds improve also cognitive function as well 3 compounds reduced glucose level.
  • No toxicity was found following in-vivo experiments in mice, detecting survival, neurological score and liver histopathology.
  • There is a clear opportunity for  an effective and well-tolerated anti-obesity drugs. Weight loss continued for 31 days after cessation of treatment and then leveled off.
  • Non toxic.

Patent Status

Granted US 9,428,448

Contact for more information:

Mel Larrosa
VP Business Development Healthcare